查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
充血性心力衰竭治療藥物的市場規模、份額和趨勢分析報告：按藥物類別（ACE 抑製劑、血管緊張素 2 阻滯劑）、分銷渠道、地區、分部預測，2022-2030 年
市場調查報告書
商品編碼
1147606

充血性心力衰竭治療藥物的市場規模、份額和趨勢分析報告：按藥物類別（ACE 抑製劑、血管緊張素 2 阻滯劑）、分銷渠道、地區、分部預測，2022-2030 年

Congestive Heart Failure Drugs Market Size, Share & Trends Analysis Report By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

充血性心力衰竭藥物的市場增長和趨勢

根據Grandview Research最新報告，2022-2030年全球充血性心力衰竭藥物市場規模將以14.60%的複合年增長率擴大，2030年將達到202.3億美元。預計充血性心力衰竭 (CHF) 患病率上升、人口老齡化導致疾病風險增加以及更好治療方法的研發進展是推動增長的關鍵因素。到 2020 年，全球將有大約 6434 萬人患有心力衰竭。此外，它在糖尿病和高血壓等疾病患者中的患病率估計很高。

為尋找更好的治療方法而進行的研究和開發的驅動力是導致多種產品出現在管道中的一個主要因素。諾和諾德的 semaglutide、Zensen 的 neucardine、拜耳的 vericiguat 和阿斯利康的 AZD4831 都是領先的候選藥物。此外，延長用於治療 CHF 的鈉-葡萄糖協同轉運蛋白 2 (SGLT2) 抑製劑的標籤批准有望推動市場增長。例如，2022 年 2 月的 Jardiance（empagliflozin）和 2020 年 5 月的 Farxiga（dapagliflozin）獲得了治療 CHF 的標籤擴展。

AstraZeneca、Bristol-Myers Squibb Company、Amgen 和 Boehringer Ingelheim 等領先企業製定了通過併購在新興市場和經濟優勢地區實現地域擴張、監管批准、聯盟和合作夥伴關係的戰略。例如，2021年2月，阿斯利康宣佈在中國批准Forxiga（達格列淨）用於合併或不合併2型糖尿病的CHF。在中國之前，它已經在美國、歐洲和日本獲得了相同適應症的批准。

COVID-19 影響了藥品的供需，使患者難以獲得醫療保健並在大流行期間減少了產品需求。此外，在研發方面，臨床試驗的實施也因法規而推遲。然而，在大流行之後，該行業加快了步伐。

充血性心力衰竭藥物市場報告要點

2021年，ACE抑製劑板塊由於高處方率和市場滲透率將佔據最大份額

按治療類別劃分，由於鈉-葡萄糖協同轉運蛋白 2 (SGLT2) 抑製劑的推出，其他部分預計在預測期內增長最快

按銷售渠道劃分，由於零售藥店與家庭保健和處方藥的密切關係，預計在預測期內將有良好的增長

2021 年，北美是最大的創收地區。這是由於主要參與者的存在、有利的資金、患者意識等。

內容

第一章調查方法及範圍

  • 市場細分和範圍
    • 細分範圍
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫：
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析
      • 方法：產品流方法
  • 調查假設
  • 二級信息列表
  • 縮寫列表
  • 目的

第 2 章執行摘要

  • 市場概覽

第 3 章充血性心力衰竭藥物市場變量、趨勢和範圍

  • 描繪滲透率和增長前景
  • 監管狀況
  • 市場驅動因素分析
    • 疾病流行率增加
    • 不斷增長的老年人口
    • 新產品的批准
    • 強大的臨床藥物管線
  • 市場製約因素分析
    • 仿製藥和標籤外藥物的市場供應情況
    • 新興經濟體的報銷方案薄弱
  • 行業分析 - 搬運工
  • PESTEL 分析（政治與法律、經濟、技術）
  • 管道階段分析

第 4 章充血性心力衰竭藥物市場：細分分析，按藥物類別，2018-2030（百萬美元）

  • 充血性心力衰竭藥物市場：藥物類別的變化分析
  • ACE 抑製劑
  • 血管緊張素 2 受體阻滯劑
  • β受體阻滯劑
  • 利尿劑
  • 醛固酮拮抗劑
  • 強心劑
  • 其他

第 5 章充血性心力衰竭藥物市場：細分分析，按分銷渠道，2018-2030 年（百萬美元）

  • 充血性心力衰竭藥物市場：分銷渠道波動分析
  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 6 章充血性心力衰竭藥物市場：按地區劃分的細分分析，2018-2030 年（百萬美元）

  • 定義和範圍
  • 2021 年和 2030 年區域市場份額分析
  • 區域市場概況
  • 2021-2030 年市場規模、預測、收入和趨勢分析
    • 北美
      • 美國
      • 加拿大
    • 歐洲
      • 英國
      • 德國
      • 西班牙
      • 法國
      • 意大利
    • 亞太地區
      • 日本
      • 中國
      • 印度
      • 韓國
      • 澳大利亞
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 多邊環境協定
      • 南非
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國

第 7 章充血性心力衰竭藥物市場：競爭分析

  • 上市公司
    • 公司市場分析
    • 競爭儀錶盤分析
    • 戰略框架
  • 私人公司
    • 主要初創企業/技術顛覆者/創新者名單
    • 本地網絡地圖
  • 公司簡介
    • 拜耳公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 諾華公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 默克公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 阿斯利康
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • BRISTOL-MYERS SQUIBB 公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 安進公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 勃林格殷格翰國際有限公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 輝瑞公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • JOHNSON &JOHNSON SERVICES, INC.
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 大塚製藥株式會社
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • 禮來公司
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
    • NOVO NORDISKA/S
      • 公司簡介
      • 財務業績
      • 產品基準
      • 戰略舉措
Product Code: GVR-4-68039-987-5

Congestive Heart Failure Drugs Market Growth & Trends:

The global congestive heart failure drugs market size is expected to reach USD 20.23 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 14.60% from 2022 to 2030. The increase in the prevalence of congestive heart failure (CHF), the rising aging population leading to increased risk of disease, and growing research and development for better treatment approaches are the key factors augmenting the growth. In 2020, around 64.34 million people worldwide were suffering from heart failure. In addition, its estimated prevalence rate is high in patients with diseases such as diabetes and hypertension.

Increasing research and development for better treatment options is a major factor behind the presence of multiple products in the pipeline. Novo Nordisk's Semaglutide, Zensun's Neucardin, Bayer's vericiguat, and AstraZeneca's AZD4831 are among the prominent drug candidates. Moreover, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is expected to fuel market growth. For instance, in February 2022, Jardiance (empagliflozin) and in May 2020, Farxiga (dapagliflozin) received label expansion for the treatment of CHF.

Key players such as AstraZeneca; Bristol-Myers Squibb Company; Amgen Inc.; and Boehringer Ingelheim are strategically engaged in geographical expansions, regulatory approvals, collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For instance, in February 2021, AstraZeneca announced the approval of Forxiga (dapagliflozin) in China, indicated for CHF with or without type-2 diabetes. Before China, the drug was already approved in the U.S., Europe, and Japan for the same indication.

COVID-19 impacted the demand and supply of drugs, and patients faced difficulty in healthcare access, resulting in a decline in product demand amid the pandemic. Due to imposed restrictions, research and development saw a setback in clinical trial proceedings. However, after the pandemic, the industry regained its pace.

Congestive Heart Failure Drugs Market Report Highlights:

  • In 2021, the ACE inhibitors segment held the largest share due to its high prescription rate and market penetration
  • By drug class, the others segment is expected to be the fastest-growing segment over the forecast period due to the launch of sodium-glucose co-transporter 2 (SGLT2) inhibitors
  • By distribution channel, the retail pharmacies segment is expected to witness lucrative growth over the forecast period due to its high compatibility with home care settings and prescription drugs
  • North America was the largest revenue-generating region in 2021. This can be attributed to the presence of key players, favorable funding assistance, and increased patient awareness

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Congestive Heart Failure Drugs Market Variables, Trends, and Scope

  • 3.1 Penetration and Growth Prospect Mapping
  • 3.2 Regulatory Landscape
  • 3.3 Market Driver Analysis
    • 3.3.1 Rising prevalence of the disease
    • 3.3.2 Growing geriatric population
    • 3.3.3 New product approvals
    • 3.3.4 Strong clinical drugs pipeline
  • 3.4 Market Restraint Analysis
    • 3.4.1 Availability of generic and off-label drugs in market
    • 3.4.2 Poor reimbursement scenarios in developing countries
  • 3.5 Industry Analysis - Porter's
  • 3.6 PESTEL Analysis (Political & Legal, Economic, and Technological)
  • 3.7 Pipeline Analysis, by Phase

Chapter 4 Congestive Heart Failure Drugs Market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

  • 4.1 Congestive Heart Failure Drugs Market: Drug Class Movement Analysis
  • 4.2 ACE Inhibitors
    • 4.2.1 ACE Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.3 Angiotensin 2 Receptor Blockers
    • 4.3.1 Angiotensin 2 Receptor Blockersmarket, 2018 - 2030 (USD Million)
  • 4.4 Beta Blockers
    • 4.4.1 Beta Blockers Market, 2018 - 2030 (USD Million)
  • 4.5 Diuretics
    • 4.5.1 Diuretics Market, 2018 - 2030 (USD Million)
  • 4.6 Aldosterone Antagonists
    • 4.6.1 Aldosterone Antagonists Market, 2018 - 2030 (USD Million)
  • 4.7 Inotropes
    • 4.7.1 Inotropes Market, 2018 - 2030 (USD Million)
  • 4.8 Others
    • 4.8.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Congestive Heart Failure Drugs Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 5.1 Congestive Heart Failure Drugs Market: Distribution Channel Movement Analysis
  • 5.2 Hospital Pharmacies
    • 5.2.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.3 Retail Pharmacies
    • 5.3.1 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.4 Online Pharmacies
    • 5.4.1 Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6 Congestive Heart Failure Drugs Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 6.1 Definition & Scope
  • 6.2 Regional Market Share Analysis, 2021 & 2030
  • 6.3 Regional Market Snapshot
  • 6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
    • 6.4.1 North America
      • 6.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 6.4.1.2 U.S.
      • 6.4.1.2.1 U.S. Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.1.3 Canada
      • 6.4.1.3.1 Canada Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
    • 6.4.2 Europe
      • 6.4.2.1 Europe Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.2.2 U.K.
      • 6.4.2.2.1 U.K. Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.2.3 Germany
      • 6.4.2.3.1 Germany Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.2.4 Spain
      • 6.4.2.4.1 Spain Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.2.5 France
      • 6.4.2.5.1 France Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.2.6 Italy
      • 6.4.2.6.1 Italy Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
    • 6.4.3 Asia Pacific
      • 6.4.3.1 Asia Pacific Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.3.2 Japan
      • 6.4.3.2.1 Japan Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.3.3 China
      • 6.4.3.3.1 China Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.3.4 India
      • 6.4.3.4.1 India Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.3.5 South Korea
      • 6.4.3.5.1 South Korea Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.3.6 Australia
      • 6.4.3.6.1 Australia Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
    • 6.4.4 Latin America
      • 6.4.4.1 Latin America Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.4.2 Brazil
      • 6.4.4.2.1 Brazil Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.4.3 Mexico
      • 6.4.4.3.1 Mexico Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.4.4 Argentina
      • 6.4.4.4.1 Argentina Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
    • 6.4.5 MEA
      • 6.4.5.1 MEA Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.5.2 South Africa
      • 6.4.5.2.1 South Africa Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.5.3 Saudi Arabia
      • 6.4.5.3.1 Saudi Arabia Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
      • 6.4.5.4 UAE
      • 6.4.5.4.1 UAE Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)

Chapter 7 Congestive Heart Failure Drugs Market: Competitive Analysis

  • 7.1 Public Companies
    • 7.1.1 Company Market Position Analysis
    • 7.1.2 Competitive Dashboard Analysis
    • 7.1.3 Strategic Framework
  • 7.2 Private Companies
    • 7.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
    • 7.2.2 Regional Network Map
  • 7.3 Company Profiles
    • 7.3.1 BAYER AG
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Financial Performance
      • 7.3.1.3 Product Benchmarking
      • 7.3.1.4 Strategic Initiatives
    • 7.3.2 NOVARTIS AG
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Financial Performance
      • 7.3.2.3 Product Benchmarking
      • 7.3.2.4 Strategic Initiatives
    • 7.3.3 MERCK & CO., INC.
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Financial Performance
      • 7.3.3.3 Product Benchmarking
      • 7.3.3.4 Strategic Initiatives
    • 7.3.4 ASTRAZENECA
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Financial Performance
      • 7.3.4.3 Product Benchmarking
      • 7.3.4.4 Strategic Initiatives
    • 7.3.5 BRISTOL-MYERS SQUIBB COMPANY
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Financial Performance
      • 7.3.5.3 Product Benchmarking
      • 7.3.5.4 Strategic Initiatives
    • 7.3.6 AMGEN INC.
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Financial Performance
      • 7.3.6.3 Product Benchmarking
      • 7.3.6.4 Strategic Initiatives
    • 7.3.7 BOEHRINGER INGELHEIMINTERNATIONAL GMBH
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Financial Performance
      • 7.3.7.3 Product Benchmarking
      • 7.3.7.4 Strategic Initiatives
    • 7.3.8 PFIZER, INC.
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Financial Performance
      • 7.3.8.3 Product Benchmarking
      • 7.3.8.4 Strategic Initiatives
    • 7.3.9 JOHNSON & JOHNSON SERVICES, INC.
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Financial Performance
      • 7.3.9.3 Product Benchmarking
      • 7.3.9.4 Strategic Initiatives
    • 7.3.10 OTSUKA PHARMACEUTICAL CO., LTD.
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Financial Performance
      • 7.3.10.3 Product Benchmarking
      • 7.3.10.4 Strategic Initiatives
    • 7.3.11 ELI LILLY AND COMPANY
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Financial Performance
      • 7.3.11.3 Product Benchmarking
      • 7.3.11.4 Strategic Initiatives
    • 7.3.12 NOVO NORDISKA/S
      • 7.3.12.1 Company Overview
      • 7.3.12.2 Financial Performance
      • 7.3.12.3 Product Benchmarking
      • 7.3.12.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Incidence of Diseases
  • Table 4 Global Congestive Heart Failure Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 11 U.S. Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Canada Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 Canada Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 16 Europe Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Germany Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 U.K. Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 U.K. Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 France Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 22 France Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Italy Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 24 Italy Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Spain Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Spain Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Asia Pacific Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 29 Asia pacific Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Japan Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 31 Japan Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 China Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 33 China Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 India Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 35 India Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 South Korea Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 37 South Korea Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Australia Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Australia Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Latin America Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 41 Latin America Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Latin America Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Brazil Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 44 Brazil Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Mexico Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Mexico Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Argentina Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Argentina Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Middle East & Africa Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 50 Middle East & Africa Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 Saudi Arabia Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Saudi Arabia Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 South Africa Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 South Africa Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 UAE Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 56 UAE Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Congestive Heart Failure Drugs Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Congestive Heart Failure Drugs Market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2021 (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Congestive Heart Failure Drugs Market driver impact
  • Fig. 14 Congestive Heart Failure Drugs Market restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's
  • Fig. 17 Strategy mapping
  • Fig. 18 Congestive Heart Failure Drugs Market: Drug Class outlook and key takeaways
  • Fig. 19 Congestive Heart Failure Drugs Market: Drug Class movement analysis & market share 2021 & 2030
  • Fig. 20 ACE Inhibitors Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Angiotensin 2 Receptor Blockers Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Beta Blockers Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Diuretics Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Aldosterone Antagonists Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Inotropes Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Congestive Heart Failure Drugs Market: Distribution Channel outlook and key takeaways
  • Fig. 28 Congestive Heart Failure Drugs Market: Distribution Channel movement analysis & market share 2021 & 2030
  • Fig. 29 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Retail and Speciality Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Congestive Heart Failure Drugs Market: Regional outlook and key takeaways
  • Fig. 33 Regional outlook, 2021 & 2030
  • Fig. 34 North America
  • Fig. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S.
  • Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Canada
  • Fig. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Europe
  • Fig. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 U.K.
  • Fig. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Germany
  • Fig. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 France
  • Fig. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Italy
  • Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Spain
  • Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific
  • Fig. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Japan
  • Fig. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • Fig. 56 China
  • Fig. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 India
  • Fig. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea
  • Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Australia
  • Fig. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America
  • Fig. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil
  • Fig. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico
  • Fig. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina
  • Fig. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East & Africa
  • Fig. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa
  • Fig. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia
  • Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 UAE
  • Fig. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Market differentiators
  • Fig. 81 Key company market share analysis, 2021
  • Fig. 82 Company market position analysis
  • Fig. 83 Competitive dashboard analysis
  • Fig. 84 Regional network map